Hans Schreiber to Cell Line, Tumor
This is a "connection" page, showing publications Hans Schreiber has written about Cell Line, Tumor.
Connection Strength
0.885
-
Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication. Cancer Immunol Res. 2017 02; 5(2):127-136.
Score: 0.083
-
Tumor-associated fibroblasts predominantly come from local and not circulating precursors. Proc Natl Acad Sci U S A. 2016 07 05; 113(27):7551-6.
Score: 0.080
-
Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation. Clin Cancer Res. 2016 06 01; 22(11):2734-43.
Score: 0.077
-
Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell. 2013 Apr 15; 23(4):516-26.
Score: 0.064
-
Progression of cancer from indolent to aggressive despite antigen retention and increased expression of interferon-gamma inducible genes. Cancer Immun. 2011 Jun 30; 11:2.
Score: 0.056
-
IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest. 2008 Apr; 118(4):1398-404.
Score: 0.045
-
Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Res. 2008 Mar 01; 68(5):1563-71.
Score: 0.045
-
Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med. 2007 Jan 22; 204(1):49-55.
Score: 0.041
-
A mutant chaperone converts a wild-type protein into a tumor-specific antigen. Science. 2006 Oct 13; 314(5797):304-8.
Score: 0.041
-
Mutant p53-specific CD8TCR-therapy combined with a CD4TCR prevents relapse of cancer and outgrowth of micrometastases. Oncoimmunology. 2025 Dec; 14(1):2514041.
Score: 0.037
-
Selection of therapeutically effective T-cell receptors from the diverse tumor-bearing repertoire. J Immunother Cancer. 2025 May 02; 13(5).
Score: 0.037
-
Long-term suppression of tumor growth by TNF requires a Stat1- and IFN regulatory factor 1-dependent IFN-gamma pathway but not IL-12 or IL-18. J Immunol. 2004 Mar 01; 172(5):3243-51.
Score: 0.034
-
The safety and efficacy of systemic delivery of a new liver-de-targeted TGFß signaling inhibiting adenovirus in an immunocompetent triple negative mouse mammary tumor model. Cancer Gene Ther. 2024 Apr; 31(4):574-585.
Score: 0.034
-
Structure-guided engineering of the affinity and specificity of CARs against Tn-glycopeptides. Proc Natl Acad Sci U S A. 2020 06 30; 117(26):15148-15159.
Score: 0.026
-
Impact of TCR Diversity on the Development of Transplanted or Chemically Induced Tumors. Cancer Immunol Res. 2020 02; 8(2):192-202.
Score: 0.025
-
Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells. Clin Cancer Res. 2020 02 01; 26(3):679-689.
Score: 0.025
-
A strategy for generating cancer-specific monoclonal antibodies to aberrant O-glycoproteins: identification of a novel dysadherin-Tn antibody. Glycobiology. 2019 04 01; 29(4):307-319.
Score: 0.024
-
Tumour ischaemia by interferon-? resembles physiological blood vessel regression. Nature. 2017 05 04; 545(7652):98-102.
Score: 0.021
-
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. Immunity. 2016 06 21; 44(6):1444-54.
Score: 0.020
-
IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner. Proc Natl Acad Sci U S A. 2013 May 14; 110(20):8158-63.
Score: 0.016
-
Design and characterization of a protein superagonist of IL-15 fused with IL-15Ra and a high-affinity T cell receptor. Biotechnol Prog. 2012 Nov-Dec; 28(6):1588-97.
Score: 0.015
-
MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR. Cancer Immunol Immunother. 2013 Feb; 62(2):359-69.
Score: 0.015
-
Recurrence of intracranial tumors following adoptive T cell therapy can be prevented by direct and indirect killing aided by high levels of tumor antigen cross-presented on stromal cells. J Immunol. 2009 Aug 01; 183(3):1828-37.
Score: 0.012
-
Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol. 2007 Aug 01; 179(3):1960-8.
Score: 0.011